FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Professur für Endokrinologie
Friedrich-Alexander-Universität Erlangen-Nürnberg
Medizinische Fakultät
Einrichtungen, die zum Universitätsklinikum Erlangen gehören
Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology
Lehrstuhl für Innere Medizin I
Overview
Publications
(88)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018)
Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al.
Conference contribution
Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR (2018)
Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, et al.
Journal article
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018)
Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al.
Journal article
Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors (2018)
Atanasov G, Tsvetkova , Struecker B, Andreou A, Bahra M, Prasad , Denecke T, et al.
Conference contribution
Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study (2018)
Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Vidal Trueba H, et al.
Conference contribution
Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018)
Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, et al.
Conference contribution
BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS (2018)
Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, et al.
Journal article
Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study (2018)
Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, et al.
Conference contribution
Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018)
Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al.
Conference contribution
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome (2018)
Dillon J, Kulke M, Warner R, Bergsland E, Welin S, O'Dorisio T, Mckee C, et al.
Conference contribution
‹
1
...
4
5
6
7
8
9
›